9 May 2013 Combined surface-enhanced Raman spectroscopy biotags and microfluidic platform for quantitative ratiometric discrimination between noncancerous and cancerous cells in flow
Author Affiliations +
Abstract
Surface-enhanced Raman spectroscopy (SERS) biotags (SBTs) that carry peptides as cell recognition moieties were made from polymer-encapsulated silver nanoparticle dimers, infused with unique Raman reporter molecules. We previously demonstrated their potential use for identification of malignant cells, a central goal in cancer research, through a multiplexed, ratiometric method that can confidently distinguish between cancerous and noncancerous epithelial prostate cells in vitro based on receptor overexpression. Progress has been made toward the application of this quantitative methodology for the identification of cancer cells in a microfluidic flow-focusing device. Beads are used as cell mimics to evaluate the devices. Cells (and beads) are simultaneously incubated with two sets of SBTs while in suspension, then injected into the device for laser interrogation under flow. Each cell event is characterized by a composite Raman spectrum, deconvoluted into its single components to ultimately determine their relative contribution. We have found that using SBTs ratiometrically can provide cell identification in flow, insensitive to normal causes of uncertainty in optical measurements such as variations in focal plane, cell concentration, autofluorescence, and turbidity.
© 2013 Society of Photo-Optical Instrumentation Engineers (SPIE)
Alessia Pallaoro, Alessia Pallaoro, Mehran Hoonejani, Mehran Hoonejani, Gary B. Braun, Gary B. Braun, Carl D. Meinhart, Carl D. Meinhart, Martin Moskovits, Martin Moskovits, } "Combined surface-enhanced Raman spectroscopy biotags and microfluidic platform for quantitative ratiometric discrimination between noncancerous and cancerous cells in flow," Journal of Nanophotonics 7(1), 073092 (9 May 2013). https://doi.org/10.1117/1.JNP.7.073092 . Submission:
JOURNAL ARTICLE
11 PAGES


SHARE
Back to Top